


Schedule at a glance



Thursday, June 21st 2007

14:00 - 16:00 Room: Amphithéâtre Bordeaux

■ PLENARY SESSION 01

Chairs: Enno Christophers (Germany), Georg Stingl (Austria), Anna Kubanova (Russia)

- 14:00 **PL 01** **PSORIASIS TODAY: INTERNATIONAL PSORIASIS NETWORK**
Louis Dubertret (France)
- 14:30 **PL 02** **QUALITY OF LIFE: WHAT RELEVANT FOR MY PATIENTS?**
Andrew Finlay (United Kingdom)
- 15:00 **PL 03** **GENETIC, PHARMACOGENOMICS AND PHARMACODYNAMICS: WHAT DOES IT MEAN FOR OUR PATIENTS?**
Anne Bowcock (USA)
- 15:30 **PL 04** **PSORIASIS PHENOTYPES: WHAT ARE THE FRONTIERS OF THE DISEASE?**
Georg Stingl (Austria)

16:30 - 18:00 Room: 341

WORKSHOP 01

■ SCORING AND MONITORING THE SEVERITY OF THE DISEASE

Chairs: Charles Ellis (USA), Jana Hercogova (Czech Republic), Jean-Jacques Grob (France)

- 16:30 **INTRODUCTION**
Charles Ellis (USA)
- 16:35 **W01** **ASSESSMENT OF DISEASE ACTIVITY AND THERAPY OUTCOME IN PSORIATIC ARTHRITIS**
Philip Mease (USA)
- 16:50 **W02** **USING PSORIASIS SEVERITY SCORES IN CLINICAL PRACTICE**
Peter Van de Kerkhof (The Netherlands)
- 17:05 **W03** **UPDATE: EDEN SURVEY OF PSORIASIS CLINICAL TRIAL METHODS**
Luigi Naldi (Italy)
- 17:20 **W04** **SCORING SEVERITY OF PSORIASIS**
Charles Ellis (USA)
- 17:35 **P 001** **INCREASED BAFF SERUM LEVEL IN PSORIASIS AND ITS CORRELATION WITH SEVERITY**
S. Samoud*, Y. Galai, R. Sghiri, N. Kenani, R. Ben Asker, R. Nouira, M. Denguezli, H. Louzir (Tunisia)
- 17:43 **P 002** **C-REACTIVE PROTEIN IN MILD TO SEVERE PSORIASIS VULGARIS**
S. Coimbra*, E. Castro, P. Rocha-Pereira, H. Oliveira, L. Belo, F. Reis, S. Rocha, A. Figueiredo, F. Teixeira, A. Santos-Silva (Portugal)

16:30 - 18:00 Room: Amphithéâtre Bordeaux

WORKSHOP 02

■ MANAGEMENT OF SEVERE CLINICAL MANIFESTATIONS

Chairs: Jean-Paul Ortonne (France), Aida Pasic (Croatia), Slavo Urbancek (Slovakia)

- 16:30 **W05** **MANAGEMENT OF PSORIATIC PATIENTS WITH SEVERE PUSTULAR PSORIASIS**
Hervé Bachelez (France)
- 16:45 **W06** **MANAGEMENT OF PSORIATIC PATIENTS WITH SEVERE PSORIATIC ARTHROPATHY**
Speaker to be determined
- 17:00 **W07** **MANAGEMENT OF ERYTHRODERMIC PSORIASIS**
Aida Pasic (Croatia)

- 17:15 **W08** **MANAGEMENT OF PSORIATIC PATIENTS WITH AIDS**
Esteban Dauden (Spain)
- 17:30 **P 003** **REASONS FOR HOSPITALIZATION OF PATIENTS WITH PSORIASIS**
F. Ishak*, K. K. Jaber, F. Robbana, S. Youssef, M. Dhaoui, N. Doss (Tunisia)
- 17:36 **P 004** **SEVERE SIDE EFFECT OF INFLIXIMAB IN A PATIENT WITH THERAPY RESISTENT PSORIASIS AND PSORIATIC ARTHRITIS**
B. Hodosi*, E. Szepes, Z. Lengyel (Hungary)
- 17:42 **P 005** **RECALCITRANT GENERALIZED PUSTULAR PSORIASIS ASSOCIATED TO DACTILITIS SUCCESSFULLY TREATED WITH INFLIXIMAB**
A. M. G. Brunasso*, N. Pimpinelli (Italy)
- 17:48 **P 006** **ERYTHRODERMIC PSORIASIS: STUDY OF 219 CASES**
S. Ghafour*, S. S. C. Chiheb, H. Benchikhi (Morocco)

16:30 - 18:00 Room: 342

Workshop 03

■ PSORIASIS IN CHILDREN AND PREGNANCY

Chairs: Carlo Gelmetti (Italy), Rana Anadolu-Brasie (Turkey), Seija-Liisa Karvonen (Finland)

- 16:30 **W09** **THE GENETICS OF PSORIASIS**
Guiseppe Novelli (Italy)
- 16:45 **W10** **PREGNANCY AND PSORIASIS: ONE DISEASE AND TWO PERSONS**
Seija-Liisa Karvonen (Finland)
- 17:00 **W11** **THE SPECTRUM OF CLINICAL PRESENTATION OF PSORIASIS, INCLUDING THE MINIMAL PSORIASIS**
Rana Anadolu-Brasie (Turkey)
- 17:15 **W12** **TOPICAL THERAPY OF PEDIATRIC PSORIASIS**
Yves de Prost (France)
- 17:30 **W13** **SYSTEMIC THERAPY INCLUDING BIOLOGIC DRUGS IN PEDIATRIC PSORIASIS**
Antonio Torrelo (Spain)
- 17:45 **P 008** **OUR EXPERIENCE IN TREATING PSORIASIS IN CHILDREN**
R. Ceovic*, S. Murat Susic, A. Pasic, J. Lipozencic, A. Basta Juzbasic (Croatia)
- 17:51 **P 009** **CHILDHOOD PSORIASIS: A CLINICAL REVIEW OF 206 CASES**
A. Dammak, A. Masmoudi, H. Eljed, T. Zaz, T. Meziou, S. Boudaya, H. Turki* (Tunisia)

Friday, June 22nd 2007

8:30 - 10:00 Room: Amphithéâtre Bordeaux

Workshop 04

■ DIFFICULT TO TREAT LOCALISATIONS

Chairs: Andreas Katsambas (Greece), Dan Forsea (Romania), Luca Bianchi (Italy)

- 8:30 **W15 TREATMENT OF PSORIASIS INVOLVING ANNO-GENITAL AREA**
Dan Forsea (Romania)
- 8:45 **W16 NAIL PSORIASIS: A THERAPEUTIC CHALLENGE**
Luca Bianchi (Italy)
- 9:00 **W17 SCALP PSORIASIS**
Andreas Katsambas (Greece)

8:30 - 10:00 Room: 342

Workshop 05

■ TOPICAL TREATMENT: WHAT TO CHOOSE AND HOW TO USE

Chairs: Lajos Kemeny (Hungary), Clarisse Rebelo (Portugal), Andris Rubins (Latvia)

- 8:30 **W18 CLASSICAL TREATMENTS: DITHRANOL AND COAL TAR**
Lajos Kemeny (Hungary)
- 8:45 **W19 VITAMIN D COMBINATION TREATMENTS**
Peter Van de Kerkhof (The Netherlands)
- 9:00 **W20 TOPICAL TREATMENT IN PATIENTS RECEIVING SYSTEMIC ANTIPSORIATIC THERAPY**
Marina Papoutsaki (Italy)
- 9:15 **W21 TOPICAL TREATMENT IN PATIENTS RECEIVING PHOTOTHERAPY**
Herbert Hönigsmann (Austria)
- 9:30 **P 010 SUCCESSFUL TREATMENT OF RECALCITRANT ACRODERMATITIS CONTINUA OF HALLOPEAU WITH TOPICAL THERAPY WITH CALCITRIOL AND TACROLIMUS 0.1% OINTMENT**
A. M. G. Brunasso*, G. Lo Scocco (Italy)
- 9:36 **P 011 EVALUATION OF THE EFFICACY OF THE COMBINATION BETAMETHASONE DIPROPIONATE AND CALCIPOTRIENE IN THE TREATMENT OF PALMO PLANTAR PSORIASIS**
C. Solovan*, M. Ciolan (Romania)
- 9:42 **P 013 A NOVEL TOPICAL TREATMENT OF PSORIASIS: INHIBITION OF NGF-INDUCED KERATINOCYTE PROLIFERATION**
L. Bertarione Rava Rossa*, S. Traversa, V. Mainero, D. Barone, C. Oderda, S. Fumero, C. Pincelli, A. Marconi (Italy)

8:30 - 10:00 Room: 341

Workshop 06

■ EPIDEMIOLOGY AND REGIONAL SPECIFICITY

Chairs: Nejib Doss (Tunisia), Hidemi Nakagawa (Japan), Jai Il Youn (Korea)

- 8:30 **W22 EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS OF JAPANESE PSORIATICS**
Hidemi Nakagawa (Japan)
- 8:45 **W23 EPIDEMIOLOGY OF PSORIASIS IN EUROPE**
Luigi Naldi (Italy)
- 9:00 **W24 PSORIASIS IN KOREA**
Jai Il Youn (Korea)
- 9:15 **W25 PSORIASIS IN KOWEIT**
Qacem Alsaleh (Koweit)

9:30 **W26** **PSORIASIS IN FRANCE AND TUNISIA: A COMPARATIVE EPIDEMIOLOGICAL DATA**

Nejib Doss (Tunisia)

9:45 **P 014** **LINKAGE ANALYSIS OF PSORIASIS IN TUNISIAN MULTIPLEX FAMILIES**

M. Ammar*, C. Bouchlaka-Souissi, A. Rebai, A. Sioud, F. Cherif, N. Doss, R. Dhaoui, A. Ben Osman, R. El Amouri, F. Hentati, A. El Gaaied, M. Mokni (Tunisia)

9:51 **P 015** **HIGH PREVALENCE OF HEPATITIS C VIRUS INFECTION IN PSORIASIS AND ASSOCIATION OF HUMAN PARVOVIRUS B19 INFECTION WITH SEVERE PSORIASIS**

N. Hannachi, S. Samoud*, R. Sghiri, Y. Galai, N. Kenani, M. Denguezli, R. Nouira, J. Boukadida (Tunisia)

10:30 - 12:30 Room: Amphithéâtre Bordeaux

PLENARY SESSION 02

Chairs: Aldo Finzi (Italy), Jasna Lipozencic (Croatia)

10:30 **PL 05** **CARDIOVASCULAR RISK IN PSORIASIS**

Jonathan Barker (United Kingdom)

11:00 **PL 06** **CO-MORBIDITY AND TREATMENT SAFETY**

Jean-Hilaire Saurat (Switzerland)

11:30 **PL 07** **MILD PSORIASIS: WHAT IS IT AND HOW TO MANAGE IT?**

Peter Van de Kerkhof (The Netherlands)

12:00 **PL 08** **THE MAIN PATHOGENETIC HYPOTHESIS IN PSORIASIS**

Frank Nestle (United Kingdom)

14:00 - 15:30 Room: 342

Workshop 07

SYSTEMIC THERAPIES: WHAT TO CHOOSE AND HOW TO USE (RETINOIDS, CYCLOSPORINE, FUMARIC ACID)

Chairs: Harald Gollnick (Germany), Giampiero Girolomoni (Italy), Jai Il Youn (Korea)

14:00 **W27** **UP-DATE FOR ROUTINE SYSTEMIC TREATMENT OF PSORIASIS BY MIXTURE OF FUMARIC ACID DERIVATIVES**

Bernd Bonnekoh (Germany)

14:15 **W28** **RETINOIDS IN PSORIASIS**

Harald Gollnick (Germany)

14:30 **W29** **CYCLOSPORIN IN PSORIASIS**

Sergio Chimenti (Italy)

14:45 **P 016** **INFLUENCE OF CYCLOSPORINE TREATMENT ON PATIENTS' MENTAL COMFORT**

H. Zelenkova*, J. Stracenska (Slovakia)

14:51 **P 017** **R1 15866 (RAMBAZOLE): A POTENTIAL ALTERNATIVE FOR RETINOIDS IN THE TREATMENT OF PSORIASIS**

C. J. Verfaillie*, P. M. Steijlen, P. C. M. van de Kerkhof, P. Stoppie, J. P. Van Wauwe, K. van Rossem (Belgium)

14:00-15:30 Room: Amphithéâtre Bordeaux

Workshop 08 Sponsored by Boehringer Ingelheim

RISK MANAGEMENT AND TREATMENT OPTIMISATION: COMBINATION AND RATIONAL STRATEGIES

Chairs: Jörg Prinz (Germany), Amrinder Jit Kanwar (India), Nikolai Tsankov (Bulgaria)

14:00 **W31** **PARADIGM FOR THE SYSTEMIC TREATMENT OF PLAQUE PSORIASIS**

Jean-Paul Ortonne (France)

14:15 **W32** **SYSTEMIC MANAGEMENT OF PSORIASIS - AN INDIAN PERSPECTIVE**

Amrinder Jit Kanwar (India)

- 14:30 **W33 RIFAMPICIN AS TREATMENT STRATEGY FOR PSORIASIS: BENEFITS AND RISKS**
Nikolai Tsankov (Bulgaria)
- 14:45 **W34 DO'S AND DON'TS IN COMBINATION OF SYSTEMIC DRUGS AND PHOTOTHERAPY**
Peter Weisenseel (Germany)
- 15:00 **W35 ROLE OF PHOTOTHERAPY IN THE MANAGEMENT OF DARKER SKIN**
Davinder Parsad (India)
- 15:15 **P 018 POSSIBILITY OF APPLICATION OF ESSENTIAL FATTY ACIDS IN TREATMENT OF PSORIASIS**
N. V. Tsiskarishvili*, T. I. Tsiskarishvili, N. I. Tsiskarishvili (Georgia)
- 15:21 **P 019 THERAPY-RESISTANT PSORIASIS TREATED WITH ADALIMUMAB AND CONCOMITANT NARROW BAND ULTRAVIOLET B PHOTOTHERAPY WITH CLEARING OF PSORIASIS**
I. Belinchon*, A. Lucas, J. Mataix, M. Perez-Crespo, J. Silvestre, I. Betlloch (Spain)
- 15:28 **P 020 CYTOGENOTOXICITY OF THERAPEUTIC MODELS USED IN PSORIASIS VULGARIS**
A. Moreiras*, S. Coimbra, P. Rocha-Pereira, H. Oliveira, L. Belo, F. Reis, A. Figueiredo, F. Teixeira, E. Bronze-da-Rocha, N. Teixeira, A. Santos-Silva (Portugal)

14:00-15:30 Room: Amphithéâtre 341

Workshop 09

■ PHOTOTHERAPIES: WHAT TO CHOOSE AND HOW TO USE

Chairs: Herbert Hönigsmann (Austria), Jose Manuel Carrascosa (Spain), Sarah Rogers (Ireland)

- 14:00 **W36 OPTIMISING NB-UVB**
Jose Manuel Carrascosa (Spain)
- 14:15 **W37 NARROWBAND UV-B (TL-O1) PHOTOTHERAPY VS ORAL 8-METHOXYPsorALEN-UV-A FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS**
Sarah Rogers (Ireland)
- 14:30 **W38 PHOTOTHERAPY: COMBINATIONS AND ROTATIONAL STRATEGIES**
Herbert Hönigsmann (Austria)
- 14:45 **W39 EXCIMER LASER**
Lajos Kemeny (Hungary)

16:00 - 17:30 Room: 342

Satellite Symposium Sponsored by Wyeth

■ REALISING THE INDIVIDUALISED TREATMENT OPPORTUNITY IN PSORIASIS

Chair : Louis Dubertret (France)

- 16:00 **CHAIRMAN'S WELCOME AND INTRODUCTION**
Louis Dubertret (France)
- 16:05 **THE TRUE BURDEN OF PSORIASIS AND IMPLICATIONS FOR TREATMENT**
Sergio Chimenti (Italy)
- 16:30 **TREATMENT OPTIONS FOR PSORIASIS IN 2007**
Hervé Bachelez (France)
- 16:55 **DELIVERING LIFE-LONG IMPROVEMENTS FOR THE PATIENT**
Frank Nestle (UK)
- 17.20 **FACULTY Q&A AND CLOSING REMARKS**

Saturday, June 23rd 2007

8:30 - 10:00 Room: Amphithéâtre Bordeaux

Workshop 10

■ SYSTEMIC THERAPIES: WHAT TO CHOOSE AND HOW TO USE (METHOTREXATE, AZATHIOPRIN, HYDROXYUREA)

Chairs: Yves Poulin (Canada), Janos Hunyadi (Hungary), Peter Arenberger (Czech Republic)

- 8:30 **INTRODUCTION**
Yves Poulin (Canada)
- 8:35 **W40 METHOTREXATE IN PSORIASIS**
Yves Poulin (Canada)
- 9:00 **W41 HYDROXYUREA AND AZATHIOPRINE IN PSORIASIS**
Lyn Guenther (Canada)
- 9:15 **W42 EXPERIENCE WITH METHOTREXATE, AZATHIOPRINE AND HYDROXYUREA IN EUROPE**
Peter Arenberger (Czech Republic), Janos Hunyadi (Hungary)
- 9:30 **P 022 METHOTREXATE: TREATMENT OF REFERENCE IN SEVERE PSORIASIS**
B. B. S. O. Omar*, A. B. A. Belbachir (Algeria)
- 9:36 **P 024 PSORIASIS AND METHOTREXATE: 93 CASES**
H. Benchikhi*, S. Skali, M. Jamali, H. Lakhdar (Morocco)
- 9:42 **P 025 TOPICAL IMMUNOMODULATORS FOR THE TREATMENT OF PSORIASIS**
P. Arenberger*, M. Arenbergerova (Czech Republic)

8:30 - 10:00 Room: 342

Workshop 11

■ ALTERNATIVE TREATMENT

Chairs: Anne-Lene Krogstad (Norway), Min Zheng (China), Michael David (Israel)

- 8:30 **W43 ALTERNATIVE THERAPY FOR PSORIASIS IN CHINA: TRADITIONAL CHINESE MEDICINE AND ACUPUNCTURE**
Min Zheng (China)
- 8:45 **W44 CLIMATE THERAPY - THE ROLE OF PATIENTS EDUCATION**
Astrid Klopstad Wahl (Norway)
- 9:00 **W45 SERUM D-VITAMINE CONCENTRATION AFTER SUN- AND UVB EXPOSURE IN PSORIASIS PATIENTS**
Amra Osmancevic (Sweden)
- 9:15 **W46 EFFECT OF SUN EXPOSURE ON T CELLS AND CYTOKINES IN PERIPHERAL BLOOD IN PSORIATIC PATIENTS. A CLINICAL TRIAL**
Elisabeth Soyland (Norway)
- 9:30 **W47 THE EXPERIENCE IN TREATING PSORIASIS BY CLIMATOTHERAPY AT THE DEAD SEA**
Michael David (Israel)
- 9:45 **P 026 CONCEPT OF A 3 MONTH ADJUVANT PARTICIPATORY PROGRAM FOR PATIENTS WITH CHRONIC DERMATOSES: FIRST RESULTS**
J. L. W. Lambert* (Belgium)
- 9:51 **P 027 XP-828L: ORAL TREATMENT DERIVED FROM WHEY PROTEIN FOR MILD TO MODERATE PSORIASIS**
R. Drouin*, Y. Poulin, C. Juneau (Canada)

10:30 - 13:00 Room: Amphithéâtre Bordeaux

■ PLENARY SESSION 03

Chairs: Berthold Rzany (Germany), Zorica Peric Hajzler (Serbia)

- 10:30 **PL 09** **PSORIASIS ARTHRITIS TODAY**
Philip Mease (USA)
- 11:00 **PL 10** **PHOTOTHERAPIES: SAFETY AND NEW APPROACH**
Michel de la Brassine (Belgium)
- 11:30 **PL 11** **CLASSICAL SYSTEMIC TREATMENTS: NEW INSIGHTS**
Menno De Rie (The Netherlands)
- 12:00 **PL 12** **BIOLOGIC: FROM CLINICAL TRIALS TO MEDICAL PRACTICE**
Sergio Chimenti (Italy)
- 12:30 **PL 12 bis** **TOPOPROTEOMA MAPPING FOR CLINICAL AND EXPERIMENTAL RESEARCH IN PSORIASIS**
Bernd Bonnekoh (Germany), Harald Gollnick (Germany)

14:00 - 15:30 Room: 342

Satellite Symposium Sponsored by IBSA-GENEVRIER

■ TARGETING THE PSORIASIS PLAQUE : A NEW APPROACH FOR A DAILY PROBLEM

Chair : Louis Dubertret (France)

- 14:00 **WELCOME AND INTRODUCTION**
- 14:05 **PSORIASIS: SMALL IS NOT NICE, SMALL IS NOT MILD**
Sarah ROGERS (Ireland)
- 14:20 **TOPICAL CORTICOTHERAPY: THE EXPERT'S OPINION**
Lajos KEMENY (Hungary)
Maria ESPOSITO (Italy)
Andreas KATSAMBAS (Greece)
- 14.50 **DEVELOPMENT STRATEGY OF A NEW TOPICAL CORTICOSTEROID PRODUCT**
Jean-Paul ORTONNE (France)
- 15:10 **FILM: CHARACTERISTICS OF A NEW MEDICATED PLASTER**
- 15.20 **DISCUSSION AND CONCLUSIONS**
- 15.30 **END OF SESSION**

16:30 - 18:30 Room: Amphithéâtre Bordeaux

■ PLENARY SESSION 04

Chairs: Min Zheng (China), Javier Ubogui (Argentina)

- 16:30 **PL 13** **PERSPECTIVES IN PSORIASIS TREATMENT**
Thomas Luger (Germany)
- 17:00 **PL 14** **BRAIN-SKIN AXIS IN PSORIASIS**
Christopher Griffiths (United Kingdom)
- 17:30 **PL 15** **INDIVIDUAL AND SOCIAL COSTS IN PSORIASIS**
Julien Lambert (Belgium)
- 18:00 **PL 16** **DEVELOPMENT OF PSORIASIS GUIDELINES IN THE WORLD**
Berthold Rzany (Germany), Wolfram STERRY (Germany)

Sunday, June 24th 2007

8:30 - 10:00 Room: Amphithéâtre Bordeaux

Workshop 12 Sponsored by Merck Serono

■ BIOLOGICS

Chairs: Hidemi Nakagawa (Japan), Esteban Dauden (Spain), Carlo Pincelli (Italy)

- 8:30 **W48 THE RATIONALE OF BIOLOGICS IN THE TREATMENT OF PSORIASIS**
Frank Nestle (United Kingdom)
- 8:45 **W49 THE ROLE OF THE DERMATOLOGIST IN THE TREATMENT OF PSORIATIC ARTHRITIS**
Nicole Selenko-Gebauer (Austria)
- 9:00 **W50 THE IDEAL POSITIONING OF BIOLOGICS IN THE TREATMENT OF PSORIASIS**
Lluís Puig (Spain)
- 9:15 **W51 CAUTIONS AND THE PROBLEMATIC SIDES OF BIOLOGICS**
Yoshinori Umezawa (Japan)
- 9:30 **P 028 ADALIMUMAB THERAPY IMPROVES THE SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PSORIASIS MORE RAPIDLY THAN EITHER METHOTREXATE OR PLACEBO: RESULTS FROM THE PHASE III CHAMPION TRIAL**
R. G. Langley, J. Saurat*, G. Stingl, M. J. McIlraith (Switzerland)
- 9:36 **P 029 RESPONSE TO ADALIMUMAB IS CONSISTENT FOR PATIENTS IN DIFFERENT SUBGROUPS: SUBANALYSES OF THE PHASE III REVEAL TRIAL IN MODERATE TO SEVERE PSORIASIS**
A. Menter*, K. A. Papp, C. Leonardi, M. J. McIlraith (USA)
- 9:42 **P 030 BIOLOGICAL AUTOIMMUNITY, LUPUS-LIKE ILLNESS AND ANTI-TNF-ALPHA AGENTS**
A. Giunta*, M. Chimenti, F. Spinelli, G. Valesini, S. Chimenti (Italy)
- 9:48 **P 031 CERTOLIZUMAB PEGOL, THE FIRST PEGYLATED ANTI-TNF ALPHA, IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS: PRELIMINARY DATA FROM A PHASE II STUDY**
J. Ortonne*, W. Sterry, C. Tasset, K. Reich (France)
- 9:54 **P 032 INFLUENCE AND VARIATION OF THE BODY MASS INDEX IN PATIENTS TREATED WITH ETANERCEPT FOR PSORIASIS**
M. Esposito*, A. Mazzotta, R. Saraceno, C. Schipani, L. Bianchi, S. Chimenti (Italy)

8:30 - 10:00 Room: 342

Workshop 13

■ EXTRACUTANEOUS MANIFESTATIONS IN PSORIASIS

Chairs: Hervé Bachelez (France), Francisco Vanaclocha (Spain), Marko Potocnik (Slovenia)

- 8:30 **W52 PSORIATIC ARTHRITIS: THE DERMATOLOGISTS VIEW**
Wolf-Henning Boehncke (Germany)
- 8:45 **W53 EXTRACUTANEOUS MANIFESTATIONS OF PSORIASIS OTHER THAN ARTHRITIS: DOES IT REALLY EXIST?**
Hervé Bachelez (France)
- 9:00 **W54 CO-MORBIDITIES AND ASSOCIATED DISEASES IN PSORIASIS: THEIR IMPACT ON CLINICAL PRACTICE**
Francisco Vanaclocha (Spain)
- 9:15 **W55 AN OVERVIEW OF EXTRACUTANEOUS SIDE EFFECTS RELATED TO SYSTEMIC THERAPIES IN PSORIASIS**
Marko Potocnik (Slovenia)
- 9:30 **W56 RHEUMATOLOGICAL MANIFESTATIONS IN PATIENTS RECEIVING BIOLOGICALS FOR SEVERE PSORIASIS**
Manuelle Viguier (France)

10:30 - 12:00 Room: 342

Workshop 14

■ COMORBIDITIES IN PSORIASIS

Chairs: Gillian Murphy (Ireland), Martine Bagot (France), Michel Le Maître (France)

10:30 **W57** **OBESITY AND PSORIASIS**
Frédéric Cambazard (France)

10:45 **W58** **ALCOHOLISM AND PSORIASIS**
Gillian Murphy (Ireland)

11:00 **W59** **TOBACCO AND PSORIASIS**
Michel Le Maître (France)

11:15 **W60** **SEVERE PSORIASIS IN MALES**
Sarah Rogers (Ireland)

11:30 **P 033** **PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS: A HOSPITAL BASED CASE-CONTROL STUDY**
P. Gisondi*, G. G. Tessari, A. Conti, S. Piaserico, S. Schianchi, A. Peserico, A. Giannetti, G. Girolomoni (Italy)

11:36 **P 034** **LIPID METABOLISM AND PSORIASIS VULGARIS**
A. Colsmán*, M. Brügel, J. Thiery, M. Sticherling (Germany)

11:42 **P 035** **TUMORAL INVASIVE T-CELL LYMPHOMA IN A PATIENT WITH PSORIASIS VULGARIS**
P. Gillard*, A. Choffray, O. Vanhooetghem, M. de la Brassinne (Belgium)

11:48 **P 036** **PSORIASIS AND DIABETES MELLITUS**
A. Khaled*, N. El Fekih, F. Zeglaoui, M. Kharfi, B. Fazaa, S. Gaigi, M. Kamoun (Tunisia)

11:54 **P 037** **VOGT-KOYANAGI-HARADA'S DISEASE ASSOCIATED WITH PSORIASIS AND AUTOIMMUNE THYROID DISEASE**
N. Kluger*, F. Mura, J. Guilhou, B. Guillot, D. Bessis (France)

10:30 - 12:30 Room: Amphithéâtre Bordeaux

■ PATIENTS ASSOCIATION & DERMATOLOGISTS MEETING

The first « club patients » meeting of the International Psoriasis Network shall be held in Palais des Congrès in Paris, Porte Maillot on Sunday, June 24th, 2007.

The aim of this meeting is to share our own experiences in our countries through:

- The presentation of successful programs dealing with psoriasis
- Different projects which could be interesting to duplicate in other countries to raise the interest of authorities and medical field in psoriasis

Likewise, we can work on The World Psoriasis Day, how to make this day more efficient and try to find a common idea (for example, we could organize the same event the same day in all countries...). Our aim is to make Psoriasis the most important subject of the day. Moreover, we can have a real impact, and the communication about Psoriasis will be improved especially on this day.

So we suggest you to gather all your ideas and we will discuss them. Our goal is to find a way to give Psoriasis its own place among other diseases.

The meeting will be opened at 10:30.

AGENDA

- Opening of the meeting by Dalila Sid-Mohand who organizes this meeting with Patricia Jimmy;
- Each country will have to present its program and/or projects about Psoriasis (and tell us what works in their own country);
- Regarding the World Psoriasis Day, on October 29th, how about organizing an open debate whose main subject would be:
 - « How to make people aware of this special day? »
 - « How to inform them about Psoriasis and the impact it has on our daily life! »

Closing of the meeting at 12:30.